A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 diabetes insufficiently controlled with insulin glargine and metformin. - GET GOAL DUO 1

Trial Profile

A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 diabetes insufficiently controlled with insulin glargine and metformin. - GET GOAL DUO 1

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Lixisenatide (Primary) ; Metformin; Thiazolidinediones
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms GETGOAL-DUO-1
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Sep 2017 Results of an exploratory analysis comparing efficacy of simultaneous administration of iGlarLixi in LixiLan-O ( N =469) trial versus sequential administration of insulin glargine followed by addition of lixisenatide in GetGoal Duo-1 ( N =223) trial, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
    • 13 Jun 2017 Results of propensity score-matched analysis to compare this study and Lixi- Lan-O Trial presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 27 Jul 2016 According to a Sanofi media release, lixisenatide (Adlyxin) has been approved by the US FDA for the treatment of adults with typre 2 diabetes based on results from GetGoal clinical program and ELIXA trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top